Lantern Pharma Inc.

NASDAQ:LTRN

Biotechnology

Healthcare
$3.93 -4.67%

-$0.19 today

Market cap
$50.14M
Beta
2.32
P/E (TTM)
-2.7
EPS (TTM)
-$1.41
52W Low $1.11High $5.74

Volume 0.10M

Average 0.68M

LTRN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Lantern Pharma Inc.NASDAQ: LTRN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$3.33M, compared with -$4.53M a year earlier. Trailing-twelve-month EBITDA was -$15.9M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +17.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.33M+18.3% QoQ
Last fiscal yearDec 2025
-$17.1M+17.6% YoY
LTMMar 2026
-$15.9M+19.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.6%+100.0%+73.4 pp
1 year+17.6%+100.0%+82.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(17.1M) USD
Year-over-year change
+17.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LTRN compares with its peers on the latest reported figures

  • LTRN's LTM Mar 2026 EBITDA of -$15.9M is the 4th highest of the 5 companies compared; the peer median is -$13.58M.
  • Its year-over-year change of +19.8% is the 2nd highest of 5, against a peer median of -52.7%.
LTRN Competitors Peer median
EBITDA for LTRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$12.18M +130.3%—34.7%
RNXTRenovoRx, Inc.LTM Mar 2026-$12.27M -63.0%—823.9%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$14.89M -54.8%——
LTRNLantern Pharma Inc.LTM Mar 2026-$15.9M +19.8%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M -50.5%——
Peer median (excluding LTRN) -$13.58M-52.7%—429.3%

Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00174.84K00
Gross Profit00(174.84K)00
Gross Margin—————
Research & Development7.57M8.6M11.89M16.13M11.51M
Selling, General & Admin5.02M5.83M5.98M6.09M6.46M
Operating Expenses12.59M14.43M17.7M22.22M17.98M
Depreciation & Amortization6.76K10.08K174.84K17.28K17.28K
EBITDA(12.36M)(14.05M)(15.79M)(20.76M)(17.1M)
EBITDA Margin—————
Operating Income(12.59M)(14.43M)(17.88M)(22.22M)(17.98M)
Operating Margin—————
Interest Income67.93K204.36K765.39K742.36K437.93K
Interest Expense0204.36K000
Other Income / Expenses228.48K172.81K1.92M1.44M859.06K
Income Before Tax(12.36M)(14.26M)(15.96M)(20.78M)(17.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.36M)(14.26M)(15.96M)(20.78M)(17.12M)
Net Margin—————
EPS (Basic)(1.13)(1.31)(1.47)(1,930.92)(1.57)
EPS (Diluted)(1.13)(1.31)(1.47)(1,930.92)(1.57)
Weighted Avg Shares10.9M10.85M10.84M10.76M10.9M
Weighted Avg Shares (Diluted)10.9M10.85M10.84M10.76M10.9M

Lantern Pharma Inc.

NASDAQ:LTRN

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.